7.02
+0(+0.00%)
Currency In USD
| Previous Close | 7.02 |
| Open | 7.02 |
| Day High | 7.02 |
| Day Low | 7.02 |
| 52-Week High | 9.67 |
| 52-Week Low | 3.08 |
| Volume | 4.54M |
| Average Volume | 1.57M |
| Market Cap | 575.59M |
| PE | -3.08 |
| EPS | -2.28 |
| Moving Average 50 Days | 6.95 |
| Moving Average 200 Days | 4.78 |
| Change | 0 |
If you invested $1000 in Accolade, Inc. (ACCD) since IPO date, it would be worth $12,763.64 as of December 25, 2025 at a share price of $7.02. Whereas If you bought $1000 worth of Accolade, Inc. (ACCD) shares 3 years ago, it would be worth $976.36 as of December 25, 2025 at a share price of $7.02.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Data not available
Accolade Stockholders Approve Merger Between Accolade and Transcarent
GlobeNewswire Inc.
Mar 27, 2025 8:05 PM GMT
SEATTLE, March 27, 2025 (GLOBE NEWSWIRE) -- Accolade (NASDAQ:ACCD) announced that Accolade stockholders voted to approve the merger with Transcarent at the Accolade special meeting of stockholders (the “Special Meeting”) held earlier today. The fin
Transcarent and Accolade Announce Expiration of Hart-Scott Rodino Waiting Period for Pending Merger Transaction
GlobeNewswire Inc.
Feb 24, 2025 10:20 PM GMT
SAN FRANCISCO and SEATTLE, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Transcarent, the One Place for Health and Care, and Accolade (NASDAQ:ACCD), a leader in health advocacy, expert medical opinions, and primary care, today announced the expiration of the w
Transcarent To Acquire Accolade
GlobeNewswire Inc.
Jan 08, 2025 1:30 PM GMT
Combined company creates industry leading platform with more than 1,400 employer and payer clients, with shared focus on consumer empowerment Transcarent’s Generative AI WayFinding and care experiences combined with Accolade’s Advocacy, Expert Medica